Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

The user experienced hair regrowth after starting finasteride in September 2025 and topical minoxidil in December 2025, despite setbacks from using tretinoin gel. Their current treatment includes dutasteride, finasteride, topical minoxidil, and dermastamping.

Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.

A user shared their 15-month hair regrowth progress using finasteride, minoxidil, biotin, increased protein intake, and derma rolling. They also improved their lifestyle by working out, quitting smoking, drinking less, and getting better sleep.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.

A 24-year-old uses microneedling, tretinoin, topical and oral minoxidil, and oral finasteride for hair growth, noticing baby hair growth and initial side effects that resolved. Another user shares a similar regimen, excluding finasteride.

The conversation is about purchasing Breezula, a hair loss treatment. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user, almost 50, has been using finasteride for 30 years and recently added oral dutasteride to address hair recession. They are now trying a new treatment stack including Minoxidil, Dutasteride, Melatonin, Rosemary oil, and Bimatoprost, along with derma stamping and Ketoconazole shampoo.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

A 35-year-old male experienced significant hair improvement using microneedling, finasteride, minoxidil, and keto shampoo. He adjusted his microneedling routine for better results.

The conversation discusses whether to wait for Breezula while using topical minoxidil to avoid side effects from finasteride. It mentions Breezula's potential release in a year and its cost and long-term use considerations.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.

The conversation is about finding non-alcoholic minoxidil options in India due to irritation from propylene glycol-based formulations. Suggestions include Tugain 5% foam, Morr Max 5%, minoxidil gel, and Morr F Aqua plus, with OP avoiding finasteride due to side effects.

The user is struggling with the high cost of RU58841 and is seeking cheaper bulk sources, considering options like Carolina Chemical. Other users discuss alternative treatments like finasteride, minoxidil, and dutasteride, with mixed experiences on effectiveness.

The conversation is about recommendations for oral minoxidil brands, specifically "Minoforce," and purchasing from reputable sellers on IndiaMart. Users discuss brand effectiveness, dosage, and shipping costs.

The conversation discusses hair loss treatments, specifically RU58841, and inquiries about its availability and cost in India. Minoxidil and finasteride are also mentioned as treatments.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The user experienced hair growth improvement using a 1.25mm microneedle weekly, oral finasteride, oral minoxidil, and rosemary oil. They plan to switch to generic finasteride and minoxidil for safety concerns.

Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Breezula is seen as a potential future treatment for hair loss, but its release is uncertain and current data is limited. Other treatments like GT20026 and pyrilutamide are discussed, but skepticism remains about their effectiveness compared to established options like finasteride and minoxidil.